Biomarkeranalytik aus Sicht des Pathologen-Reference-Cited by-同舟云学术

Biomarkeranalytik aus Sicht des Pathologen

Published:2013-10-24 Issue:11 Volume:56 Page:1502-1508
ISSN:1436-9990
Container-title:Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
language:de
Short-container-title:Bundesgesundheitsbl.

Author:

Buettner R.,Heydt C.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health

Link

http://link.springer.com/content/pdf/10.1007/s00103-013-1823-1.pdf

Reference50 articles.

1. Deutsche Krebsgesellschaft E.V. (2012) Krebshäufigkeit – die aktuellen Zahlen. http://www.krebsgesellschaft.de/krebshaeufigkeit,111267.html (Zugegriffen: 02.02.2013)

2. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

3. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

5. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wo ist die molekulare Pathologie sinnvoll?;Der Onkologe;2015-12-16

2. The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma;The Clinical Respiratory Journal;2015-09-21

3. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO);Annals of Oncology;2014-09